Project Grant R01AI181671
Award Date
8/21/24
Completion Date
6/30/29
Dollars Obligated
$650K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Nebraska, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $910,905.00 to the Scripps Research Institute to advance HIV vaccine development using a lipid nanodisc platform. The key objectives are to: Solve the structures of engineered transmembrane HIV envelope (Env) proteins incorporated into lipid nanodiscs in complex with broadly neutralizing antibodies targeting the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $440,700.00 to New York University School of Medicine to conduct research focused on improving HIV vaccine design. The key goals are to: 1) Design and validate an immunogen targeting the V2B neutralization epitope on the HIV/SIV viral spike, and 2) Test the combination of vaccine-elicited anti-V2B...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $745,752 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Mayo Clinic. The funding supports research to develop an HIV-1 vaccine that can generate strong immune responses at mucosal surfaces, the primary sites of HIV exposure. Key aspects of the project include: Evaluating the ability of a "single-cycle" adenovirus (SC-AD) vaccine platform to amplify antigen production...
The federal Project Grant award R01AI187016 for $737,761.00, awarded on August 1, 2024 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to enhance HIV prevention through a vaccine approach that promotes durable immunity. The key objectives are to induce robust CD4 T follicular helper (TFH) cells, which are essential for vigorous B cell activity within germinal centers, to facilitate the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $824,331 to the Trustees of Boston College to conduct research on "Understanding Formation and Dynamics of the SIV Reservoir." The project aims to investigate the early establishment and persistence of viral reservoirs in HIV/SIV infection, with a focus on the potential role of naive CD4+ T cells in...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $183,602 to The University of North Texas Health Science Center at Fort Worth to support research on engineering a simian-compatible version of HIV-1. The goal is to construct an "HSIV" virus, which has an HIV-1 backbone with minimal SIV gene fragments, to enable more effective studies of AIDS pathogenesis...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the dynamics and evolution of HIV Gag and GagPol processing. The $752,745 award aims to use molecular dynamics simulations, single-molecule FRET imaging, and cryo-electron tomography to probe the structure and dynamics of Gag and GagPol that enable ordered processing by the viral...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Program (CFDA 93.855), provides $208,875 to Duke University to develop a multivalent mRNA HIV vaccine targeting recently circulating subtype C HIV strains. The goal is to elicit broadly neutralizing antibodies that can recognize and neutralize diverse HIV subtypes, with a focus on the V2-apex region of the viral envelope protein. The 3-year...
This Project Grant award, valued at $3,302,677.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award will support research at Oregon Health & Science University (OHSU) focused on using multimodal positron emission tomography (PET) imaging to directly visualize sites of simian immunodeficiency virus (SIV) persistence and identify early tissue foci of viral rebound in...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,332,155 to Emory University to conduct research focused on developing immunotherapies to cure HIV in SHIV-infected infant macaques. The key objectives are to evaluate strategies that leverage broadly neutralizing antibodies (bNAbs) in combination with virus reactivation, innate immune stimulation, and attachment...